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Surface plasmon resonanceMAGUKs to the actin cytoskeleton was ﬁrst established by the interaction of
erythrocyte p55 with the FERM domain of protein 4.1R. Subsequently, it was reported that p55 binds to a 51-
amino acid peptide, encoded by exon 10, located within the FERM domain of protein 4.1R. In this study, we
investigated the nature of the p55–FERM domain binding interface and show that p55 binds to a second 35-
amino acid peptide, encoded by an alternatively spliced exon 5, located within the FERM domain of protein
4.1R. Competition and Surface Plasmon Resonance-binding measurements suggest that the peptides encoded
by exons 5 and 10 bind to independent sites within the D5 domain of p55. Interestingly, the full length
135 kDa isoform of protein 4.1R containing both exons 5 and 10 was targeted exclusively to the plasma
membrane of epithelial cells whereas the same isoform without exon 5 completely lost its membrane
localization capacity. Together, these results indicate that p55 binds to two distinct sites within the FERM
domain, and the alternatively spliced exon 5 is necessary for the membrane targeting of protein 4.1R in
epithelial cells. Since sequences similar to the exon 5-peptide of protein 4.1R and D5 domain of p55 are
conserved in many proteins, our ﬁndings suggest that a similar mechanism may govern the membrane
targeting of other FERM domain containing proteins.
© 2008 Elsevier B.V. All rights reserved.1. Introduction
Membrane-associated guanylate kinase homologues (MAGUKs)
are a family of proteins characterized by the presence of one or three
PDZ domains, an SH3 domain, and a catalytically inactive guanylate
kinase-like (GUK) domain, all of which function as protein–protein
interactionmodules [1]. It is believed that MAGUKs serve a scaffolding
role by linking the transmembrane proteins to the cytoskeleton, thus
regulating events such as synapse formation, cell–cell adhesion, and
cell polarity [2,3]. Erythroid p55, encoded by the Mpp1 gene, is one of
the two founding members of the MAGUK family of proteins [4,5]. It
forms a ternary complex with the transmembrane protein glyco-R for Radixin, M for Moesin);
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ppressor protein; p55, human
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l rights reserved.phorin C and the cytoskeletal protein 4.1R, which is located at the
spectrin–actin junctions, also called the junctional complex, in
erythrocytes [6–9]. Previously, we localized the protein 4.1R-binding
sitewithin a positively charged 39-amino acid region located between
the SH3 and GUK domains of p55 [7,8]. This 39-amino acid sequence in
p55, termed D5 domain, is also conserved in the Drosophila discs large
tumor suppressor (Dlg) where it has been designated as the HOOK
domain and plays a critical role in the membrane targeting of Dlg in
vivo [10,11]. A similar functional role of the HOOK domain has been
demonstrated in the membrane targeting of mammalian homologue
of Dlg tumor suppressor [12]. The primary structure of the D5 domain
of p55 is characterized by a cluster of lysine residues (KKKKYKDK) that
are fairly conserved among other members of the MAGUK family
including CASK and human Dlg [13,14]. For example, the HOOK
domain of CASK binds to the FERM domain of protein 4.1R [13]
whereas the alternatively spliced I3 sequence located within the
HOOK domain of human Dlg mediates its binding to the FERM domain
of protein 4.1R [12,14]. In addition, the I3 sequence mediates the
targeting of human Dlg to the cell–cell contact sites in epithelial cells
[12]. Based on these studies, it is now believed that a speciﬁc binding
element located within the D5/HOOK/I3 sequence plays a critical role
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vertebrate and non-vertebrate cells.
Protein 4.1R (Red cell) is the prototypical member of the protein 4.1
family of cytoskeletal proteins including protein 4.1N (Neuron), 4.1B
(Brain), and 4.1G (General) [15–18]. Protein 4.1R is a critical
component of the erythrocyte membrane skeleton stabilizing the
horizontal interactions between spectrin and actin [15]. The physio-
logical signiﬁcance of protein 4.1R was ﬁrst revealed when its absence
in patients with inherited hemolytic anemia hereditary elliptocytosis
caused signiﬁcant red cell membrane instability and cell shape
abnormalities [19,20]. In addition, the protein 4.1R null red cells
show a secondary loss of p55 and glycophorin C in their plasma
membrane, further validating the existence of the ternary complex in
vivo [6]. The primary genetic defect in patients with hereditary
elliptocytosis is located in the promoter region of 4.1R gene that is
speciﬁc for the erythroid lineage, and does not affect the expression of
the non-erythroid isoforms of protein 4.1R transcribed by at least two
alternate promoters [20–23].
Considerable evidence now supports the view that the 135 kDa
isoform of protein 4.1R plays a functional role in the regulation of cell
division and growth, although the precise physiological basis of this
function in the proliferation and differentiation pathways remains
unknown [24–26]. Like other family members, the protein 4.1R is
expressed in a variety of non-erythroid cells and its gene function is
regulated by a complex array of alternatively spliced exons in both
erythroid and non-erythroid cells [21,23]. A single gene encoding
protein 4.1R is located on human chromosome 1p36 [27], and a
combination of constitutive and alternatively spliced exons generates
two major polypeptides of protein 4.1R in the mammalian cells
[28,29]. The 135 kDa isoform of protein 4.1R, transcribed from an
upstream initiation codon, is found generally in the non-erythroid
cells whereas the 80 kDa isoform, transcribed from the downstream
initiation codon of the same gene, is found primarily in themature red
blood cells [21,30,31].
Using native p55 and protein 4.1R isolated from human red blood
cells, our group ﬁrst showed that p55 binds to a protease-resistant
amino terminal 30 kDa fragment of protein 4.1R, which we later
named as the FERM domain [32]. We demonstrated that the native
FERM domain of protein 4.1R binds to the D5 domain of p55 [7,8]. In a
subsequent study, Nunomura et al. [33] mapped the p55-binding site
within the FERM domain of protein 4.1R and showed that p55 binds to
a 51-amino acid peptide encoded by the constitutive exon 10 of
protein 4.1R. The same study further mapped the p55-binding site
within the 31-amino acid sequence located near the C-terminus of the
exon 10-encoded 51-amino acid peptide of protein 4.1R [33]. However,
with the elucidation of the crystal structure of the FERM domain of
protein 4.1R [34], it became apparent that the charge distribution at
the p55–protein 4.1R binding interface is inconsistent to support a
robust interaction between the D5 domain of p55 and the exon 10-
encoded peptide of the FERM domain of protein 4.1R. These
observations also implied that the p55–protein 4.1R interaction
would not be amenable to regulation by alternative splicing mechan-
isms since both the 51-amino acid peptide of protein 4.1R and D5
domain of p55 are encoded by constitutive exons in their respective
genes [30,35]. The binding interface between p55 and protein 4.1R is
therefore in contrast to the known interaction between human Dlg
and protein 4.1R regulated by alternative splicing of the exon encoding
the I3 peptide of human Dlg tumor suppressor [12,14].
In this study, we re-evaluated the nature of the p55 binding site(s)
within the FERM domain of protein 4.1R using a combination of
recombinant fusion proteins expressed in bacteria and insect cells. Our
results demonstrate that p55 binds to a second site within the FERM
domain of protein 4.1R, and this 35-amino acid binding site is encoded
by an alternatively spliced exon 5 of the protein 4.1R gene. In addition,
the presence of the exon 5-encoded peptide is essential for the
intracellular targeting of full length 135 kDa isoform of protein 4.1R tothe plasma membrane of epithelial cells. These ﬁndings provide a
framework for the selection of appropriate constructs for the ongoing
crystallization studies of the p55–FERM domain complex, and may
have general implications for the subcellular targeting of other FERM
domain containing proteins.
2. Materials and methods
2.1. Recombinant FERM domain, exon 5-peptide, and exon 10-peptide of
protein 4.1R
FERM domain constructs of human protein 4.1R were engineered.
One construct contained exon 5 (FERM) whereas the second construct
had exon 5 deleted (FERMΔE5). Both constructs, starting from the
second ATG (nucleotide 801) in exon 4 to phenylalanine in exon 12
(nucleotide 1694), were PCR-ampliﬁed with the primer set (5′-
CCGGAATTCATGCACTGCAAGGTTTCT-3′ and 5′-AAACTGCAGT-
TAAAATTTGGATCCTAGCGC-3′) using cDNA from the corresponding
protein 4.1R isoforms as templates. Two additional constructs of the
FERM domainweremadewhere either exon 10 or both exons 5 and 10
were deleted. The inserts were cloned into pMal-c2X and pMal-p2X
vectors (NE BioLabs) that produce N-terminal Maltose Binding Protein
(MBP)-fusion proteins when expressed in E. coli DH-5α cells. The
pMal-c2X and pMal-p2X vectors are engineered to facilitate recombi-
nant protein expression in the bacterial cytoplasm and periplasm,
respectively (NE BioLabs).
The exon 5 and exon 10 encoded sequences of protein 4.1R were
ampliﬁed from the FERM domain constructs of protein 4.1R with each
speciﬁc set of primers. Speciﬁc primers (5′-ATCGGATCCGTGGAGAAA-
CATGCTAAGGGA-3′ and 5′-CTCGAATTCCTTAGAGGTTGCGTTATCCCA-
3′) for exon 5 ampliﬁed a 129 bp fragment whereas speciﬁc primers
for exon 10 (5′-ATCGGATCCGACTTGGAAGGAGTAGATATC-3′ and 5′-
CTCGAATTCCTCTCCAGGCCGAATCTTGAT-3′) ampliﬁed a 171 bp frag-
ment. Appropriate restriction sites were introduced at the beginning
of each primer to facilitate subsequent cloning of the ampliﬁed PCR
bands. The corresponding inserts were cloned in pMal-c2X and
pET32a (Novagen) vectors for the expression of MBP and His-
Thioredoxin (Trx)-fusion proteins, respectively. Nucleotide sequences
of all clones were veriﬁed by DNA sequencing. For the expression of
recombinant proteins in E. coli, a single bacterial colony containing
the desired plasmid was grown overnight at 37 °C in 5.0 ml of Luria
Broth (LB) supplemented with 100 μg/ml Ampicillin. The bacterial
culture was diluted in 300 ml of the same media, and grown to mid-
log phase (optical density of 0.6) before induction with 0.2 mM
isopropyl-1-thio-β-D-galactopyranoside (IPTG). The culture was
further incubated for 12 h at 25 °C. Cells were harvested by
centrifugation, the cell pellet was resuspended in 20 ml of lysis buffer
(phosphate-buffered saline with 0.1% Triton X-100), and the cell
suspension was sonicated. The cell free extract was prepared by
centrifugation, and the MBP-fusion proteins and His-Trx-fusion
proteins were afﬁnity puriﬁed using amylose-coupled resin (NE
BioLabs) and Ni-NTA resin (QIAGEN), respectively. It is noteworthy
that the Trx-exon 10 encoded peptide was largely insoluble when
expressed in bacteria. Some residual recombinant protein could be
recovered on beads, but the lack of soluble protein precluded its use in
the competition assays.
2.2. Full length protein 4.1R
Full length 135 kDa protein 4.1R cDNA containing exon 5 was made
as described previously [27]. This construct was made in the
pcDNA3.1/His C vector (Invitrogen), which contains the Xpress
epitope at the N-terminus. Full length protein 4.1R construct without
exon 5 was made by deleting the exon 5 sequence from the above
clone, using the Quick Change site-directed mutagenesis kit (Strata-
gene). DNA sequencing and Western blot of lysate from transfected
Table 1
Binding constants for p55 interaction with the FERM domains and individual peptides
Ligand Analyte kass (1/[M·s])×10−4 kdiss (1/s)×103 kD (nM)
His-p55 MBP-FERM 6.7±0.1 4.7±0.1 70±3
MBP-FERMΔexon 5 2.2±0.04 2.9±0.1 132±7
MBP-exon 5 16±0.3 2.4±0.2 15±1.5
MBP-exon 10 6±0.3 1.8±0.1 30±3
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size.
2.3. Recombinant p55
Recombinant full length human erythrocyte p55 cDNA was
expressed in E. coli and Sf9 insect cells and used for protein 4.1-
binding experiments. The GST-p55 was expressed and puriﬁed as
described previously [8]. Human p55 cDNA was cloned in the pQE9
(QIAGEN) vector for expression as a His-tagged p55 fusion protein in E.
coli, which was puriﬁed using Ni-NTA resin as indicated above. For the
expression of p55 in insect cells, the p55 cDNAwas cloned in pFastBac
HTb vector (Invitrogen) for the expression of His-tagged p55 fusion
protein. Recombinant baculovirus was obtained according to the
protocol of Bac-to-Bac expression system (Invitrogen). His-tagged p55
was puriﬁed from cell free supernatant using the Ni-NTA agarose
column. The recombinant p55 protein expressed in bacteria, and the
His-p55 fusion expressed in Sf9 cells, behaved identically for binding
to the FERM domain of human protein 4.1R.
2.4. In vitro protein–protein interaction assays
Recombinant MBP-fusion proteins of FERM, FERMΔE5, exon 5, and
exon 10 of protein 4.1R bound to the maltose-coupled resin were
incubated with puriﬁed recombinant His-p55 in the binding buffer
(PBS supplemented with 0.1% Triton X-100) at 4 °C for 2 hours. The
beads were washed four times with the binding buffer, and bound
proteins were resolved by 10% sodium dodecyl sulfate-polyacrylamide
gel electrophoresis (SDS-PAGE), and analyzed by Western blottingFig. 1. Schematic representation of p55 and protein 4.1R domains. (A) Linear schematic diag
domain of protein 4.1R. (B) Linear domain diagram of human protein 4.1R. The FERM domain c
mutated FERM (EED→AAA) construct was engineered by deleting the EED sequence to AAA
domain of band 3 [36]. The FERMΔExon 5 construct was made by deleting exon 5 from theusing an anti-p55 monoclonal antibody. For competition assays, an
increasing amount of Trx-exon 5 recombinant protein was used in the
binding reaction as a competitor. BSA at 1% concentration was
included in the binding buffer (PBS, 0.1% Triton X-100) to reduce the
non-speciﬁc background.
2.5. Surface Plasmon Resonance measurements
The protein–protein interactions weremeasured using the BIAcore
1000 system (Pharmacia Biacore AB/GE Healthcare). To analyze
interactions between His-p55, MBP-FERM, MBP-FERMΔE5, MBP-
exon 5, andMBP-exon 10, the His-p55 fusion proteinwas immobilized
on the CM5 sensor chip. The binding reactions were performed at
25 °C. To analyze the strength of various interactions, recombinant
proteins (analyte) were passed over the immobilized His-p55 surface
at concentrations ranging from 50–400 nM. The experiments were
performed at 25 °C at 30 μl/min ﬂow rate for the kinetic measure-
ments except the immobilization and regeneration processes, which
were carried out at 5.0 μl/min ﬂow rate. The composition of the
running buffer was 10 mM HEPES, 150 mM NaCl, 3.4 mM EDTA, and
0.005% P20 (pH 7.4). The composition of immobilization buffer for His-
p55 was 10 mM sodium acetate, pH 3.5, and the regeneration buffer
was 100 mM NaCl and 10 mM NaOH, pH 11.7. The results shown in
Table 1 represent the outcome of three separate experiments for MBP-
FERM, MBP-exon 5, MBP-exon 10, and two experiments for the MBP-
FERMΔexon5 construct. Binding data, analyzed by the BIAcore
software, were consistent in all cases, and ﬁt well with the 1:1
binding site model.
2.6. Tissue culture and immunoﬂuorescence analysis
MDCK cells were maintained in the Dulbecco's modiﬁed Eagle's
medium supplemented with 10% fetal calf serum. MDCK cells, stably
transfected with 135 kDa protein 4.1R either with or without exon 5,
were selected by treating the transfected cells with 600 μg/ml
Geneticin (Invitrogen) for 2 weeks. DNA transfection was carried out
using LipofectAMINE 2000 (Invitrogen). For immunoﬂuorescence
analysis, Geneticin-selected cells were plated on the glass cover slipsram of human erythrocyte p55. The D5 domain contains the binding site for the FERM
onstruct contains both the alternatively spliced exon 5 and the constitutive exon 10. The
located within exon 5. The LEEDY sequence in exon 5 is known to bind the cytoplasmic
FERM domain construct by in vitro mutagenesis.
Fig. 3. Independent binding of exon 5 and exon 10 encoded peptides of FERM domain to
p55. (A) Lack of competition of p55 binding to MBP-exon 10 and Trx-exon 5 fusion
proteins. The recombinant His-p55 (0.64 μg/ml or 11.6 nM) was pre-incubated for
2 hours at 4 °C with increasing amounts of Trx-exon 5 peptide (0.2, 0.9, 1.9, and 4.9 μg/
ml/196 nM) before the addition of MBP-exon 10 coupled to the amylose beads (∼0.5 μg
per assay). The mixture was incubated for 1 hour at 4 °C. The beads were washed,
harvested, and bound proteins resolved by SDS-PAGE using 10% polyacrylamide gels.
The binding of His-p55 to exon 10 was detected byWestern blotting using amonoclonal
antibody against p55. (B) As an alternate strategy, the MBP-exon 5 fusion protein was
incubated with the GST-p55 fusion protein coupled to the glutathione Sepharose beads.
The p55 binding sites were saturated by three consecutive incubations of MBP-exon 5
fusion protein. After washing, the glutathione beads were incubatedwith the MBP-exon
10 fusion protein for 2 hours at 4 °C. Proteins bound to the beads were harvested,
washed four times, and analyzed by SDS-PAGE and Western blotting. The blots were
developed using a commercial polyclonal antibody against MBP. Note that the closely-
spaced doublet of MBP-exon 5 and MBP-exon 10 peptides is more visible at the low
exposure of the material shown in lane 4. Lane 1 is the negative control GST-coupled
beads incubated with both MBP-Exon 5 and Exon 10, which showed no detectable
binding. Lane 2 is the MBP-exon 5 bound to GST-p55 and lane 3 is the MBP-exon 10
bound to GST-p55.
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10 minutes followed by soaking in cold acetone for 10 seconds, air
dried, and processed for staining with the corresponding antibodies.
The primary antibody was anti-Xpress monoclonal (Invitrogen) with
1/500 dilution, and the secondary antibody was Texas Red-conjugated
goat anti mouse IgG (Molecular Probes) with 1/1000 dilution.
3. Results
3.1. Direct binding of protein 4.1 FERM domain isoforms with p55
To characterize the nature of the p55-binding sites within the
FERM domain of human protein 4.1R, we ﬁrst established in vitro
binding assays using puriﬁed recombinant proteins. We generated a
maltose-binding fusion protein of the FERM domain of protein 4.1R
(Figs. 1 and 2). The MBP-FERM domain protein was immobilized onto
the amylose beads and incubated with recombinant His-p55 fusion
protein expressed in bacteria. The binding of soluble His-p55 to the
beads-bound MBP-FERM domain was erratic particularly when
stringent washing conditions were used to remove the unbound
material from the beads. While investigating the cause of these
variable binding data, we noticed that the FERM domain construct of
the human protein 4.1R lacked the alternatively spliced exon 5 but
contained the constitutive exon 10, which has been previously shown
to encode the p55-binding site [33]. Since this FERM domain construct
was missing exon 5, we designated it as MBP-FERMΔExon 5 (Fig. 1B).
To examine the possibility that the peptide encoded by exon 5 may
facilitate protein 4.1R binding to p55, a second cDNA construct was
made that contained both exons 5 and 10 and designated as MBP-
FERM domain (Fig. 1B). Except for the presence of exon 5, the two
MBP-FERM and MBP-FERMΔExon 5 constructs are identical.
The MBP-FERM and MBP-FERMΔExon 5 fusion proteins were
expressed and puriﬁed under identical conditions from the bacterial
cytoplasm (Fig. 2A). Both MBP-FERM domain fusion proteins were
soluble when expressed in the bacterial cytoplasm or periplasm
(data not shown). We made two additional cDNA constructs of exonFig. 2. Expression of FERM domain constructs and p55 binding assay. (A) Coomassie
blue stained gel showing recombinant MBP fusion proteins used for the binding assays.
MBP (lanes 1), MBP-FERMΔExon 5 (lane 2), and MBP-FERM (lane 3). Fusion proteins
shown in lanes 1–3 were expressed in the cytoplasm of E. coli using the pMal-c2X
expression vector. Fusion proteins were also expressed in the bacterial periplasm using
the pMal-p2X vector (data not shown). Results were identical with both preparations.
(B) Coomassie blue stained gel showing recombinant MBP (lane 1), MBP-exon 5 (lane 2),
and MBP-exon 10 (lane 3) used for the binding studies. These recombinant proteins
were expressed in the bacterial cytoplasm. Western blot based detection of His-p55
recovered by the MBP-fusion protein conjugated amylose-beads is shown on the right.
A monoclonal antibody raised against human erythrocyte p55 was used for Western
blotting.5-peptide and exon 10-peptide expressing individually as MBP fusion
proteins (Fig. 2B). The MBP-FERM domain fusion proteins were
immobilized to the amylose beads and used to measure the binding
of soluble His-p55. All four MBP fusion proteins pulled down His-p55
indicating that both peptides encoded by exons 5 and 10 can bind to
p55 under these conditions (Fig. 2). No measurable p55-binding was
detected with the MBP protein alone. These results indicate that the
erythrocyte p55 can bind to two independent peptides located
within the FERM domain of protein 4.1R. It is noteworthy that a
previous study has shown direct binding of band 3 to the LEEDY
sequence located within the exon 5-encoded peptide of protein 4.1R
[36]. To investigate whether both band 3 and p55 can bind to the
same binding site on the exon 5-encoded peptide of protein 4.1R, we
generated a new FERM domain construct where the LEEDY sequence
of exon 5-peptide was changed to LAAAY sequence by in vitro
mutagenesis (Fig. 1B). The binding of His-p55 to wild type and
mutated FERM domains was similar suggesting that band 3 and p55
do not share the same binding site within the exon 5-peptide (F1
lobe or N-lobe) of protein 4.1R.
3.2. Protein 4.1R-FERM domain containing both exon 5 and exon 10
binds to p55 with higher afﬁnity
To examine the role of exon 5-encoded peptide on the p55-binding
capacity of protein 4.1R in the context of the entire FERM domain,
individual interactions were quantiﬁed using the BIAcore-based Surface
Plasmon Resonance assay. Bacterially expressed His-p55 was immobi-
lized on theCM5 sensor chip and its binding afﬁnitywith theMBP-FERM
and MBP-FERMΔExon 5 fusion proteins was quantiﬁed. MBP at 500 nM
concentration was used as a negative control showing negligible
interaction with the ligand surface. The kdiss and kD values, which
represent the dissociation rate constant and equilibrium constant,
respectively,were calculatedusing a series of analyte concentrationsand
Fig. 4. BIAcore quantiﬁcation of p55 interactionwith peptides encoded by exons 5 and 10. The Surface Plasmon Resonance (SPR) techniquewas used to quantify the interaction of p55
with the FERM domain of protein 4.1R with and without exon 5-peptide (A–C). The same technique was used to demonstrate the non-competition of exon 5 and exon 10 peptide-
binding sites to His-p55 (D). Sensograms were obtained from SPR analysis of the interaction between His-p55 and the FERM domain constructs of protein 4.1R. Recombinant His-p55
protein was immobilized on the CM5 sensor chip and the MBP-FERM domain fusion proteins were injected as an analyte. The wild type His-p55 protein was expressed either in the
bacterial cytoplasm or in Sf9 cells with no effect on its binding properties. (A) The binding properties of MBP-FERM and MBP-FERMΔExon 5 fusion proteins to the immobilized His-
p55 were measured at 100 nM concentration of each analyte protein. Sensogram of 100 nM MBP (analyte) binding to His-p55 on the chip was used as a negative control. The
sensograms were generated using a 30 μl/min analyte ﬂow rate (BIAcore 1000 instrument) and included a 3-minute association and a 5-minute dissociation section. (B) Sensograms
of theMBP-FERM domain fusion protein (analyte) injected at various concentrations ranging from 50–400 nM. MBP alone at 500 nMwas used as a negative control. The ﬂow ratewas
30 μl/min over the immobilized His-p55 surface yielding a kD value of 70 nM. (C) Sensograms of the MBP-FERMΔExon 5 domain fusion protein (analyte) injected at various
concentrations ranging from 50–400 nM. The MBP at 500 nMwas used as a negative control. The ﬂow rate was 30 μl/min over the immobilized His-p55 surface yielding a kD value of
132 nM. (D) The MBP-exon 5 fusion protein (1 μM) was injected over the His-p55 surface, followed by the washing of the chip surface with the running buffer for 25 min at 5 μl/min
ﬂow rate. This step was repeated three times, followed by the injection of 1.0 μMMBP-exon 10 for 25minutes and washing of the chip surface with the running buffer for 25minutes.
The sensograms show that the exon 10-peptide can bind to the p55 surface that is already saturated with the exon 5-peptide.
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equilibrium methods yielded consistent results. The kdiss and kD values
of respective interactions are shown in Table 1. The kdiss value between
His-p55 andMBP-FERM fusion proteinwas 4.7±0.1×10−3 (1/s), whereas
the kdiss value between His-p55 and MBP-FERMΔExon 5 fusion protein
was 2.9±0.1×10−3 (1/s). The calculated kD values between His-p55 and
MBP-FERM, and His-p55 and FERMΔExon 5 fusion proteins were
calculated to be 70±3 nM and 132±7 nM, respectively. These
measurements indicate that the association rate of MBP-FERM domain
to His-p55 is relatively faster than that of MBP-FERMΔExon 5 domain,
thus making the overall afﬁnity of His-p55 to MBP-FERM fusion protein
approximately twotimeshigher than thatofMBP-FERMΔExon5domain
(Table 1). It is noteworthy that the quantitative values, as shown in
Table 1, were obtained by normalizing the amount of each MBP fusion
protein (analyte).
To investigate the individual binding of exon 5 and exon 10
encoded peptides, in vitro binding assays were performed demon-
strating that His-p55 can interact with both MBP-exon 5 and MBP-
exon 10 peptides but not with the control MBP (Fig. 2). Moreover, the
amount of boundMBP fusion peptides was normalized and the ratio of
protein to Western blot signal of His-p55 was determined. These
results suggested that the binding of His-p55 with MBP-exon 5
peptide was relatively stronger as compared to the binding between
His-p55 andMBP-exon 10 peptide (data not shown). To quantify these
interactions, His-p55 was immobilized on the CM5 sensor chip and
the binding of MBP fusion peptides encoded by exons 5 and 10 was
measured using the BIAcore SPR assay. The MBP was used as a
negative control. The kdiss values between His-p55 and MBP-exon 5peptide, and His-p55 andMBP-exon 10 peptidewere determined to be
2.4±0.2×10−3 (1/s) and 1.8±0.1×10−3 (1/s), respectively. The corre-
sponding kD values between His-p55 and MBP-exon 5 peptide, and
His-p55 and MBP-exon 10 peptide were calculated to be 15±1.5 nM
and 30±3 nM, respectively (Table 1). These measurements indicate
that both MBP-exon 5 and MBP-exon 10 peptides can bind to His-p55,
and the association rate of MBP-exon 5 peptide to His-p55 is relatively
faster as compared to the binding between MBP-exon 10 peptide and
His-p55, thus making the overall afﬁnity of the MBP-exon 5 peptide to
His-p55 approximately two times higher than that of MBP-exon 10
peptide (Table 1). At this stage, we do not know the reason why the
individual peptides encoded by exons 5 and 10 bind to His-p55 with
relatively higher afﬁnity as compared to when they are presented in
the context of the entire FERM domain. (Table 1). This ﬁnding can be
rationalized by greater steric accessibility and molar concentration of
the binding sites when presented as individual peptides. The FERM
domain is a highly compact protease-resistant module, and it is likely
that additional regulatory cues may be required to fully expose the
individual binding sites in the intact domain. Consistent with this
notion, we have previously demonstrated that the length of peptides
can inﬂuence their binding properties with the PDZ domains even
when the extended segments do not encode any binding residues [9].
3.3. Competition studies suggest that both exon 5 and exon-10 peptides
bind to independent sites on p55
Next, we examined whether the peptides encoded by exons 5 and
10 can compete for the same binding site on p55. To test this
Fig. 5. Localization of heterologous protein 4.1R in MDCK epithelial cells. The 135 kDa
full-length isoform of protein 4.1R including exons 5 and 10 was expressed in the MDCK
cells (upper panel), whereas the same isoform of protein 4.1R containing exon 10 but
lacking exon 5 was also expressed in the MDCK cells under identical conditions (lower
panel). The expression of heterologous proteins was established by staining with an
anti-Xpress antibody to detect the Xpress-tagged isoforms of protein 4.1R. The merged
images of protein 4.1R in red and DAPI staining in blue are shown in each panel.
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soluble fusion protein in the bacterial cytoplasm. The Trx-exon 5
peptide was used as a competitor to inhibit the binding of p55 to the
MBP-exon 10 peptide immobilized on the amylose beads (Fig. 3). No
inhibition of p55-binding to the immobilized MBP-exon 10 peptide by
the Trx-exon 5 peptide was observed suggesting that these peptides
bind to independent sites within p55 (Fig. 3A). To further investigate
the independence of the two binding sites, we used a GST-p55 fusion
protein that was coupled to the glutathione-Sepharose beads and then
incubated with the MBP-exon 5 peptide by reciprocal rounds of three
incubations in order to saturate all the exon 5-peptide binding sites
accessible on immobilized p55. The bead-bound GST-p55 saturated
with the MBP-exon 5 peptide was washed and then incubated with
the MBP-exon 10 peptide. The binding of MBP fusion proteins to the
glutathione beads were analyzed by SDS-PAGE and Western blotting
using an anti-MBP antibody. Both fusion peptides of MBP-exon 5 and
MBP-exon 10 were pulled down simultaneously with the GST-p55
beads (Fig. 3B, lane 4). Together, these results suggest that the
recombinant peptides encoded by exons 5 and 10 bind to two
independent binding sites within p55.
The existence of independent binding sites for peptides encoded
by exons 5 and -10 on p55 was further investigated using the
BIAcore assay. Two experimental approaches were used to quantify
these interactions. The experiments were performed at 25 °C at 5 μl/
min ﬂow rate. Freshly prepared His-p55 was immobilized on the
CM5 sensor chip before each assay. First, the MBP-exon 5 fusion
peptide was injected on the His-p55 surface, and the surface was
washed with the running buffer at 5 μl/min to stabilize the baseline.
This step was repeated several times to saturate all the accessible
MBP-exon 5 peptide binding sites on His-p55. After the stabilization
of the exon 5-peptide bound His-p55 surface, the MBP-exon 10
peptide was injected to determine whether the MBP-exon 10 peptide
can bind to the His-p55 surface that is already saturated with the
MBP-exon 5 peptide. The SPR measurements show that the MBP-
exon 10 peptide can bind to the His-p55 surface that is already
saturated with the MBP-exon 5 peptide (Fig. 4D), indicating that the
exon 5 and -10 peptides likely bind to non-overlapping sites on p55
and there is no apparent steric hindrance phenomena. In addition, a
reverse experiment was performed where the His-p55 surface was
ﬁrst saturated with the MBP-exon 10 peptide, and then the binding
of MBP-exon 5 peptide was measured. Again, the MBP-exon 5
peptide bound to the His-p55 surface further conﬁrming the
independence of the two binding sites on p55 (data not shown).
We have previously shown that the FERM domain isolated from
native protein 4.1R binds to 39-amino acid sequence ﬂanked by the
SH3 and Guanylate kinase domains of p55 [8]. This 39-amino acid
sequence of p55 contains an unusually large number of lysine
residues [8]. We believe that a simple mutagenesis or truncation
approach may not be feasible to assess the independence of exon 5
and exon 10 peptide binding sites on p55. This is partly because the
limited truncation of the 39 amino acid D5 domain of p55 leads to
highly unstable D5 domain. Therefore, we believe that the co-
crystallization of the p55–FERM domain complex provides the most
rigorous means of precisely mapping the binding interface between
p55 and protein 4.1R in future studies.
3.4. Exon 5-peptide is essential for the membrane targeting of protein
4.1R in epithelial cells
Our results indicate that the exon 5-peptide provides a second
binding site on the FERM domain of protein 4.1R for p55, and this
binding site is of higher afﬁnity than the exon 10-peptide. To assess
the physiological signiﬁcance of this observation in non-erythroid
cells, we generated two mammalian expression constructs of full
length protein 4.1R (135 kDa) with and without exon 5. Protein 4.1
family proteins, such as protein 4.1R [37], 4.1N [38], as well as theirDrosophila homologue, Coracle [39] are important components of
the lateral plasma membrane of polarized epithelial cells. Consistent
with these observations, the full length protein 4.1R (135 kDa), which
contained both exons 5 and 10, localized efﬁciently to the lateral
membrane when expressed in the MDCK epithelial cells (Fig. 5, upper
panel). In contrast, the same protein 4.1R construct from where the
alternatively spliced exon 5 was deleted by in vitro mutagenesis
completely lost its lateral membrane localization and exhibited a
punctate distribution throughout the cytoplasm (Fig. 5, lower panel).
In summary, these results demonstrate that the protein–protein
interaction(s) mediated by the exon 5-encoded peptide plays a critical
role for the lateral membrane targeting of protein 4.1R in the
mammalian epithelial cells.
4. Discussion
This study was initiated to elucidate the molecular basis of the
binding interface between human erythrocyte p55 and the FERM
domain of protein 4.1R. We examined the interaction of p55 with the
FERM domain of protein 4.1R using several independent approaches.
First, we generated and expressed a GST-FERM domain fusion protein
of protein 4.1R and tested its binding with the His-p55 recombinant
protein. Our pull-down binding assays indicated that the GST-FERM
Fig. 6. Schematic presentation of p55 interactions with protein 4.1R and membrane targeting in epithelial cells. (A) The D5 domain of p55 contains two binding sites for the FERM
domain of protein 4.1R. The exon 5-peptide is located in the F1 lobe whereas the exon 10-peptide is located in the F3 lobe. (B) The presence of alternatively spliced exon 5-peptide is
essential for the membrane targeting of protein 4.1R in the epithelial cells. Members of the p55-subfamily of MAGUKs are likely candidates for the recruitment of protein 4.1R to the
plasma membrane. (C) Ribbon diagram and charge distribution surface of the FERM domain of human erythrocyte 4.1R; adapted from reference [34]. The respective locations of the
p55-binding sites are indicated by arrows in the FERM domain.
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not be used reliably in the conventional bead-binding assays. To
overcome this limitation, we cloned and expressed the FERM domain
as a maltose binding protein (MBP) fusion in bacteria. The FERM
domain was cloned into both cytoplasmic and periplasmic expression
vectors to take into account the effect of disulphide bond pairing on
the refolding of MBP-FERM domain proteins. The histidine-tagged p55
protein was expressed in bacteria as well as in Sf9 cells using the
baculovirus expression system. Binding between His-p55 and MBP-
FERM domain was measured by the pull-down and BIAcore assays.
Our measurements indicated that there was no difference in the
binding capacity of the MBP-FERM domain expressed in either the
bacterial cytoplasm or periplasm. Also, the binding capacity of His-p55
expressed in either bacteria or Sf9 cells was also similar (data not
shown). Using these reagents, our results indicate that both
constructs, MBP-FERM domain and MBP-FERMΔExon 5 domain, canbind to His-p55. Moreover, individual peptides encoded by either exon
5 or exon 10 can also bind to p55. These data suggest that p55 binds to
a second site within the FERM domain of protein 4.1R, and the
presence of exon 5-encoded peptide is necessary for optimal and
stable binding between the FERM domain and p55.
Our identiﬁcation of exon 5-encoded peptide as the higher afﬁnity
binding site for p55 is consistent with the charge distribution within
the FERM domain of protein 4.1R [34]. The constitutive exon 10-
peptide is located in the C-lobe (also called the F3 lobe) of the FERM
domain, whereas the alternatively spliced exon 5-peptide is located
within the N-lobe (also called the F1 lobe) of the FERM domain of
protein 4.1R [34] (Fig. 6). There are several negatively charged residues
present within the F1 lobe that could potentially bind to the cluster of
positively charged lysine residues present within the D5 domain
of p55. It is also noteworthy that we have previously reported
the binding stoichiometry of p55–protein 4.1 interaction by
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is required to saturate all the binding sites on the FERM domain of
protein 4.1 [7]. Finally, our ﬁndings imply that the binding interaction
between p55 and protein 4.1R can be regulated through alternative
splicing of exon 5within the FERM domain of protein 4.1R (Fig. 6). This
model is similar to the hDlg tumor suppressor where its alternatively
spliced I3 sequence regulates hDlg binding to the FERM domain of
protein 4.1R [12, 14]. Together, the p55–4.1R and hDlg–4.1R interac-
tions exemplify two distinct regulatory controls of the same binding
interface between MAGUKs and the membrane cytoskeleton.
The results reported in this manuscript are consistent with a
previous study by Nunomura et al. [33] that suggested p55 binds to
the peptide encoded by the constitutive exon 10 of the FERM domain
of protein 4.1R. However, our ﬁnding that p55 binds to the peptide
encoded by the alternatively spliced exon 5 of the FERM domain
appear to be inconsistent with the Nunomura et al. [33] where they
have reported that p55 does not bind to the GST-FERM domain
construct that lacks exon 10 but retains exon 5. At this stage, we do not
know the reason for this discrepancy. To investigate this issue further,
however, we ﬁrst attempted to express the MBP-FERM domain
construct lacking both exons 5 and 10. The deletion of constitutive
exon 10 and alternatively spliced exon 5 was not feasible as no
recombinant MBP-FERM domain could be detected in bacteria (data
not shown). In addition, we made another MBP-FERM domain
construct where we deleted the exon 10 but retained exon 5. Again,
the expression of this construct resulted in highly unstable protein
with most of the recombinant MBP-FERM domain trapped in the
bacterial inclusion bodies. We tested multiple clones for protein
expressionwith no success. Based on these observations, we conclude
that the deletion of constitutive exon 10 will lead to the disruption of
the highly-folded compact structure of the FERM domain of protein
4.1R. Therefore, we recommend that any recombinant FERM domain
expressed without exon 10 must be ﬁrst tested rigorously for its
folding and stability properties prior to its use in protein binding
assays.
To evaluate the biological signiﬁcance of the exon 5-encoded
peptide, we tested the intracellular targeting of full length protein 4.1R
(135 kDa) in transfected mammalian epithelial cells. Interestingly,
only the protein 4.1R isoform containing exons 5 and 10 was targeted
to the plasmamembranewhereas protein 4.1R containing constitutive
exon 10 but lacking exon 5 failed to associate with the plasma
membrane and remained in the cytosol. These results demonstrate
that the presence of exon 5-peptide is essential for the intracellular
targeting of protein 4.1R to the plasma membrane of epithelial cells.
The presence of highly conserved exon 5-peptides in many other
proteins including the putative lung tumor suppressor, tyrosine
phosphatase, and NF2 tumor suppressor suggest that this sequence
could mediate their binding to p55-related MAGUKs in a variety of
other tissues. At this stage, we do not know the identity of the protein
that binds to exon 5-peptide of protein 4.1R in the kidney epithelial
cells. We tested the protein expression level of p55 in the MDCK cells
by Western blotting, and found that p55 is not detectable by this
technique. Since p55 is very sensitive to proteolysis, it is likely that
more sensitive approaches are required to detect p55 in epithelia.
Notwithstanding the apparent absence of p55 in the MDCK cells,
several p55-like MAGUK proteins are expressed in the MDCK cells
including CASK, Dlg2, Dlg3, Pals-1, and Pals-2. Several of them have
been shown to localize to the lateral plasma membrane in the MDCK
cells, and are known to interact with the FERM domain of protein 4.1R.
We speculate that one of these proteins, or a combination of them, is a
potential candidate for mediating the exon 5-peptide dependent
targeting of protein 4.1R in epithelial cells. In summary, the novel
binding interface assembled by the exon 5-peptide of protein 4.1R and
the D5 domain of p55 or a related MAGUK suggests a newmechanism
for the intracellular targeting of FERM domain containing proteins to
the plasma membrane.Acknowledgements
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